Skip to main content
. Author manuscript; available in PMC: 2010 Oct 12.
Published in final edited form as: Clin Cancer Res. 2008 Jun 1;14(11):3386–3394. doi: 10.1158/1078-0432.CCR-07-1616

Table 3.

RNA expression of targets assessed by gene expression profiling of 9 LGGs and 6 HGGs

Target gene (probe ID) Average intensity HGG Average intensity LGG Present in HGG Present in LGG Permutation P
PDGFRβ (1771_at) 600.4 488.8 67% 43% 0.457
PDGFRα (1731_at) 9,957.8 6,896.0 100% 100% 0.218
EGFR (1537_at) 2,389.2 −41.3 67% 0% 0.003
EGFR (37327_at) 987.6 −39.1 33% 0% 0.003
AKT1 (1564_at) 2,402.6 388.9 67% 43% 0.095
p44 MAPK (1000_at) 1,685.6 2,034.0 83% 100% 0.111
p42 MAPK (976_s_at) 227.4 226.8 50% 57% 0.994
FRAP1 (267_at) 111.6 98.9 50% 57% 0.823
FRAP1 (40139_at) 851.0 891.8 100% 100% 0.772
PDGFB (1573_at) 48.3 −110.9 0% 14% 0.319
PDGFA (35703_at) 2,388.0 828.4 83% 86% 0.056
PDAP1 (38757_at) 293.7 221.4 83% 14% 0.372
PDAP1 (38758_at) 5,055.5 2,822.5 100% 100% 0.001
EGF (1542_at) 399.0 409.9 17% 14% 0.914
PTEN (1434_at) 183.9 203.9 50% 86% 0.587
PTEN (39552_at) 283.0 316.3 67% 71% 0.536
PI3K (36287_at) 109.3 120.4 33% 14% 0.726
PI3K (35373_at) 533.5 1,742.7 67% 100% 0.015

NOTE: Shaded areas indicate genes with significant (P < 0.01, dark shade) or near-significant (P < 0.10, light shade) differential overexpression by HGG or LGG.